-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725

Benzinga·11/03/2026 17:49:17
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.